L. Lupinacci

发表

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

K. Syrigos, K. O'Byrne, Keunchil Park, 2019, The New England journal of medicine.

Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices

A. Cardona, O. Arrieta, Z. Zatarain-Barrón, 2018, Oncology.

Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227

K. Syrigos, Keunchil Park, H. Borghaei, 2020 .

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

L. Urban, K. O'Byrne, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

K. O'Byrne, S. Ramalingam, M. Hellmann, 2019, Annals of Oncology.

Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)

R. Rosell, A. Cardona, L. Raez, 2019, Thoracic cancer.

Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.

D. Planchard, J. Bosch-Barrera, G. Zalcman, 2022, European journal of cancer.

Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting

M. Rizzo, G. Recondo, L. Lupinacci, 2021, International Journal of Clinical Oncology.

Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.

M. Rizzo, G. Recondo, R. Kowalyszyn, 2020, Clinical lung cancer.

P86.18 Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina.

V. Denninghoff, G. Recondo, H. Rivello, 2021 .

P84.22 Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina

M. Rizzo, C. Martín, G. Recondo, 2021 .

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

L. Urban, K. O'Byrne, S. Ramalingam, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

P. Ascierto, M. Burotto, T. Ciuleanu, 2022, Cancer Research.

Effect of immunotherapy at any line of treatment on survival in Hispanic patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).

R. Rosell, C. Rolfo, L. Raez, 2019, Journal of Clinical Oncology.

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

T. Ciuleanu, J. Vuky, G. Kollia, 2024, Journal for immunotherapy of cancer.